GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (FRA:0C1) » Definitions » Short-Term Debt

Atreca (FRA:0C1) Short-Term Debt : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Atreca Short-Term Debt?

Atreca's Short-Term Debt for the quarter that ended in Sep. 2023 was €0.00 Mil.


Atreca Short-Term Debt Historical Data

The historical data trend for Atreca's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Short-Term Debt Chart

Atreca Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Atreca Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Atreca Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Atreca Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Atreca's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Atreca (FRA:0C1) Business Description

Traded in Other Exchanges
Address
835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Atreca (FRA:0C1) Headlines

No Headlines